The effect of radiotherapy target area and glial fibrillary acidic protein (GFAP) on the prognosis of high-grade glioma and its mechanism

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046667

Enrollment

Unknown

Registered

2021-05-26

Start date

2022-01-01

Completion date

Unknown

Last updated

2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High Grade Glioma

Interventions

Experimental group1:2019NRG guide target area delineation

Experimental group2:EORTC target area delineation

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Surgery has been performed; 2. Pathologically diagnosed as WHOIII, WHOIV grade glioma; 3. Aged 18 to 80 years; 4. No serious vital organ dysfunction; 5. No distant metastasis before treatment; 6. Have complete postoperative pathological results and intraoperative specimens; 7. The patient and family members have given their consent.

Exclusion criteria

Exclusion criteria: 1. Those with a history of radiotherapy, chemotherapy, and surgery; 2. Those with medical-related diseases that severely affected surgery; 3. Those who withdrew due to inability to tolerate the adverse effects of treatment; 3. Those who cannot be followed up regularly.

Design outcomes

Primary

Measure	Time frame
progress free survival (PFS);	—

Secondary

Measure	Time frame
overall survival (OS);acute and late toxic reactions;	—

Countries

China

Contacts

Public ContactLiu Feng

Department of Radiation Oncology, Hunan Cancer Hospital

liufeng820111@163.com+86 18613985727

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026